ZEB1

Summary

ZEB1 (zinc finger E-box binding homeobox 1, HGNC:11642) is a protein-coding gene on chromosome 10p11.22, encoding Zinc finger E-box-binding homeobox 1 (P37275). Acts as a transcriptional repressor. In precision oncology, ZEB1 Expression confers sensitivity to Salinomycin in Mantle Cell Lymphoma (CIViC Level D); 4 further curated variant–drug associations are listed below.

This gene encodes a zinc finger transcription factor. The encoded protein likely plays a role in transcriptional repression of interleukin 2. Mutations in this gene have been associated with posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Alternatively spliced transcript variants encoding different isoforms have been described.

Source: NCBI Gene 6935 — RefSeq curated summary.

At a glance

• Gene–disease (curated): posterior polymorphous corneal dystrophy 3 (Definitive, GenCC) — +4 more curated relationships
• GWAS associations: 5
• Clinical variants (ClinVar): 209 total — 21 pathogenic, 7 likely-pathogenic
• Phenotypes (HPO): 32
• Precision-oncology evidence (CIViC): 5 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 6 cancer types
• Transcription factor: yes — 70 downstream targets (CollecTRI)
• MANE Select transcript: NM_001174096

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11642
Approved symbol	ZEB1
Name	zinc finger E-box binding homeobox 1
Location	10p11.22
Locus type	gene with protein product
Status	Approved
Aliases	BZP, ZEB, AREB6, NIL-2-A, Zfhep, Zfhx1a, FECD6
Ensembl gene	ENSG00000148516
Ensembl biotype	protein_coding
OMIM	189909
Entrez	6935

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 9 protein_coding, 9 retained_intron, 6 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000320985, ENST00000424869, ENST00000437844, ENST00000446923, ENST00000488625, ENST00000493835, ENST00000542815, ENST00000542879, ENST00000557827, ENST00000558440, ENST00000558655, ENST00000558832, ENST00000558863, ENST00000559496, ENST00000559858, ENST00000560196, ENST00000560721, ENST00000560909, ENST00000561061, ENST00000561212, ENST00000561304, ENST00000606161, ENST00000606671, ENST00000860471, ENST00000860472

RefSeq mRNA: 41 — MANE Select: NM_001174096 NM_001128128, NM_001174093, NM_001174094, NM_001174095, NM_001174096, NM_001323638, NM_001323641, NM_001323642, NM_001323643, NM_001323644, NM_001323645, NM_001323646, NM_001323647, NM_001323648, NM_001323649, NM_001323650, NM_001323651, NM_001323652, NM_001323653, NM_001323654, NM_001323655, NM_001323656, NM_001323657, NM_001323658, NM_001323659, NM_001323660, NM_001323661, NM_001323662, NM_001323663, NM_001323664, NM_001323665, NM_001323666, NM_001323671, NM_001323672, NM_001323673, NM_001323674, NM_001323675, NM_001323676, NM_001323677, NM_001323678, NM_030751

CCDS: CCDS44370, CCDS53505, CCDS53506, CCDS53507, CCDS7169

Canonical transcript exons

ENST00000424869 — 9 exons

Exon	Start	End
ENSE00003587924	31495776	31495838
ENSE00003695302	31523933	31524113
ENSE00003695612	31520126	31521936
ENSE00003699576	31461037	31461237
ENSE00003699919	31319216	31319292
ENSE00003701577	31514603	31514708
ENSE00003702391	31502348	31502509
ENSE00003725201	31510673	31510875
ENSE00003907264	31526672	31529804

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 99.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.8704 / max 1065.2756, expressed in 1518 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104601	23.4152	1444
104605	0.9899	310
104599	0.8649	380
104598	0.4393	179
104600	0.3406	180
104602	0.2829	163
104603	0.2582	116
104604	0.1661	67
104606	0.1132	48

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	99.15	gold quality
colonic epithelium	UBERON:0000397	98.41	gold quality
tendon	UBERON:0000043	98.37	gold quality
blood vessel layer	UBERON:0004797	98.24	gold quality
decidua	UBERON:0002450	98.20	gold quality
cranial nerve II	UBERON:0000941	98.17	gold quality
gluteal muscle	UBERON:0002000	98.13	gold quality
endothelial cell	CL:0000115	97.70	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.70	gold quality
biceps brachii	UBERON:0001507	97.65	gold quality
tendon of biceps brachii	UBERON:0008188	97.52	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.46	gold quality
cauda epididymis	UBERON:0004360	97.37	gold quality
stromal cell of endometrium	CL:0002255	96.90	gold quality
triceps brachii	UBERON:0001509	96.77	gold quality
ganglionic eminence	UBERON:0004023	96.65	gold quality
cartilage tissue	UBERON:0002418	96.60	gold quality
heart right ventricle	UBERON:0002080	96.57	gold quality
pericardium	UBERON:0002407	96.53	gold quality
synovial joint	UBERON:0002217	96.16	gold quality
diaphragm	UBERON:0001103	95.99	gold quality
periodontal ligament	UBERON:0008266	95.73	gold quality
parietal pleura	UBERON:0002400	95.58	gold quality
pleura	UBERON:0000977	95.53	gold quality
myometrium	UBERON:0001296	95.52	gold quality
sural nerve	UBERON:0015488	95.49	gold quality
visceral pleura	UBERON:0002401	95.21	gold quality
saphenous vein	UBERON:0007318	95.20	gold quality
seminal vesicle	UBERON:0000998	95.08	gold quality
entorhinal cortex	UBERON:0002728	94.95	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 7.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	65.86
E-CURD-119	yes	41.25
E-GEOD-135922	yes	35.32
E-HCAD-25	yes	16.45
E-GEOD-83139	yes	7.02
E-ENAD-27	yes	6.13
E-CURD-112	no	2.56
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

70 targets.

Target	Regulation
ACTG2	Unknown
ADAM2
AR	Unknown
ATP1A1	Activation
BCL6	Repression
BGLAP	Repression
BMI1	Activation
CCN2
CCN6
CCNG2	Activation
CD4	Unknown
CDH1	Activation
CDH13	Unknown
CDH17
CDH2	Activation
CDH5	Repression
CDK2	Activation
CDK4	Activation
CDKN1A	Unknown
CDKN2A
CDKN2B	Repression
COL1A1	Repression
COL1A2	Repression
COL2A1	Unknown
COL4A3	Unknown
CRYBB1
CTNNB1	Repression
CXADR	Repression
EPCAM	Repression
ESR1	Unknown

JASPAR motifs

Motif	Name	Family
MA0103.2	ZEB1	HD-ZF factors
MA0103.3	ZEB1	HD-ZF factors
MA0103.4	ZEB1	HD-ZF factors

JASPAR matrix evidence (PMIDs): PMID:8065305

Upstream regulators (CollecTRI, top): CTNNB1, DAB2IP, E2F1, EP300, ERG, ESR1, ETS1, FLYWCH1, GATA3, GLI2, GRHL2, HOXA5, KAT2B, LBX1, LMO2, MITF, NEUROD2, NFKB, OVOL2, PCGF2, PGR, RELA, SALL4, SATB2, SIX1, SNAI1, TCF7L2, TWIST1, ZEB2

miRNA regulators (miRDB)

215 targeting ZEB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-1229-3P	99.97	66.49	906

Literature-anchored findings (GeneRIF, showing 40)

• ZEB1 plays a role in repressing E-cadherin and MUC1 in epithelial cells [ZEB-1] (PMID:12161443)
• These data provide the first demonstration that Zfhep is post-translationally modified. (PMID:12163027)
• Data show that ZEB-1/deltaEF1 and ZEB-2/SIP1 are regulators of transforming growth factor beta/bone morphogenetic protein signaling, with opposing effects on this pathway. (PMID:12743038)
• while ZEB-1/deltaEF1 binds to p300 and promotes the formation of a p300-Smad transcriptional complex, ZEB-2/SIP1 acts as a repressor by recruiting CtBP (PMID:12743039)
• an activator of transcription whose action may be DNA-context and cell-type specific, but not species specific. (PMID:14965470)
• Data demonstrate that DNA methylation contributes to increased levels of p73 in Fanconi anemia cells by hampering the binding of the transcriptional repressor ZEB to an intronic regulatory region of the p73 gene. (PMID:16087177)
• In colon cancer parients, the correlation between the expression of SNAIL and the downregulation of E-cadherin (CDH1) is lost when ZEB1 is overexpressed (PMID:16203744)
• Levels of expression of CtBP and p300 are critical for the action of SNAIL and ZEB1, which have a pivotal role in levels of epithelial-mesenchymsal transitionin human colon carcinoma. (PMID:16804902)
• zinc-finger-enhancer protein 1 (ZEB1) is the crucial transcriptional repressor of BM components in CRCs. (PMID:16952552)
• The transcriptional repression of PKP3 by ZEB1 contributes to ZEB1-mediated disintegration of intercellular adhesion and epithelial to mesenchymal transition. (PMID:17391671)
• Four novel pathogenic mutations were identified in four families; two deletions, one nonsense, and one duplication within exon 7 in the ZEB1 gene at 10p11.2. Czech patients were genotyped for a founder haplotype and lack of 20p11.2 locus segregation. (PMID:17437275)
• Upregulation of ZEB1 is associated with colon and breast cancer progression (PMID:17486063)
• The Zfhx1a-1 gene is autoregulated in part by negative feedback on its own promoter which is, in turn, modified by the availability of the negative dominant isoform Zfhx1a-2. (PMID:17610840)
• TCF8 gene mutations are associated with Posterior polymorphous corneal dystrophy and abdominal hernia (PMID:17935237)
• Based on these observations we suggest that bHLH factors recruit NFI to enhance skeletal muscle Na(+) channel expression. (PMID:17936922)
• The identification of a novel missense mutation in only one of the patients implied that TCF8 does not play a significant role in the pathogenesis of FECD in this Chinese population. (PMID:18172091)
• ZEB1 is a crucial promoter of malignant tumor progression. (PMID:18199550)
• These results lead to a new hypothesis that Snail and ZEB1 are downstream of CCN6 and play a critical role in CCN6-mediated regulation of E-cadherin in breast cancer. (PMID:18321996)
• Data show that miR-200 and -205 microRNAs cooperatively regulate expression of the E-cadherin transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also known as ZEB2), factors previously implicated in EMT and tumour metastasis. (PMID:18376396)
• loss of expression of the miR-200 family members may play a critical role in the repression of E-cadherin by ZEB1 and ZEB2 during EMT, thereby enhancing migration and invasion during cancer progression. (PMID:18411277)
• Down-regulation of TCF8 expression in ATLL cells was associated with resistance to TGF-beta1, a well-known characteristic of ATLL cells, suggesting that escape from TGF-beta1-mediated growth inhibition is important in the pathogenesis of ATLL (PMID:18467597)
• These results indicate that ZEB1 triggers an microRNA-mediated feedforward loop that stabilizes the epithelial-mesenchymal transition and promotes invasion of cancer cells. (PMID:18483486)
• ZEB1 may be a biomarker of aggressive endometrial cancers at high risk of recurrence. (PMID:18487993)
• These data support the contention that high ZEB1 encourages gynecologic carcinoma progression. (PMID:18622689)
• A double-negative feedback loop controlling ZEB1-SIP1 and miR-200 family expression. (PMID:18829540)
• TCF8 activates R-Ras, another class of angiogenic regulator, to suppress angiogenesis by a mechanism other than a transcriptional attenuator. (PMID:19116136)
• These findings suggest that Zeb1 represses T-cadherin expression and thus increases the invasive activity of gallbladder cancer. (PMID:19116147)
• DeltaEF1 controls the mesenchymal phenotype and drives erlotinib resistance in HNSCC cells (PMID:19147758)
• E-cadherin, beta-catenin, and ZEB1 have roles in malignant progression of cancer [review] (PMID:19153669)
• The results demonstrate that ZEB-1 directly inhibits SEMA3F expression in lung cancer cells. (PMID:19177200)
• The pro-survival response of neurons, initiated through the rapid induction of p63, is mediated ultimately by the transcriptional repression of a pro-apoptotic isoform of p73 by ZEB1. (PMID:19194497)
• Integral role for TCF8 in the regulation of pathologic angiogenesis, and possible use of TCF8 as a target for therapeutic intervention in cancer. (PMID:19208835)
• These results extend the role of epithelial-to-mesenchymal transition in metastasis to transendothelial migration and implicate ZEB1 and N-cadherin in this process in prostate cancer cells. (PMID:19225155)
• The detailed clinical features of posterior polymorphous corneal dystrophy (PPCD) associated with a novel ZEB1 mutation are supportive of the previously proposed range of phenotype parameters. (PMID:19432861)
• Immunohistochemical analysis of E-cadherin and Zeb-1 in primary tumors confirmed that expression of the two proteins was mutually exclusive. (PMID:19584296)
• Ladybird homeobox 1 (LBX1), a developmentally regulated homeobox gene, directs expression of the known EMT inducers ZEB1, ZEB2, Snail1, and transforming growth factor beta2 (TGFB2). (PMID:19651985)
• CtBP2 monomer interacts with a major CtBP-dependent repressor ZEB and HDAC and that the interaction of the two factors with the CtBP2 monomer was mutually exclusive. (PMID:19754958)
• these results indicate that ZEB1 and AR regulate each other to promote cell migration in triple negative breast cancer cells (PMID:19921427)
• report that ZEB1 not only promotes tumour cell dissemination, but is also necessary for the tumour-initiating capacity of pancreatic and colorectal cancer cells. (PMID:19935649)
• ZEB1 mutations may account for posterior polymorphous corneal dystrophy in 18 to 30% of cases, with the majority of the mutations in exons 5 and 7. (PMID:19997581)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zeb1b	ENSDARG00000013207
danio_rerio	zeb1a	ENSDARG00000016788
mus_musculus	Zeb1	ENSMUSG00000024238
rattus_norvegicus	Zeb1	ENSRNOG00000017863

Paralogs (1): ZEB2 (ENSG00000169554)

Protein

Protein identifiers

Zinc finger E-box-binding homeobox 1 — P37275 (reviewed: P37275)

Alternative names: NIL-2-A zinc finger protein, Negative regulator of IL2, Transcription factor 8

All UniProt accessions (5): P37275, F6TDF5, F6U0D0, H0YMD3, H0YND9

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Represses RCOR1 transcription activation during neurogenesis. Represses transcription by binding to the E box (5’-CANNTG-3’). In the absence of TGFB1, acts as a repressor of COL1A2 transcription via binding to the E-box in the upstream enhancer region.

Subunit / interactions. Interacts (via N-terminus) with SMARCA4/BRG1.

Subcellular location. Nucleus.

Tissue specificity. Colocalizes with SMARCA4/BRG1 in E-cadherin-negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas (at protein level). Expressed in heart and skeletal muscle, but not in liver, spleen, or pancreas.

Post-translational modifications. Ubiquitinated, leading to degradation in a proteasome-dependent manner. Deubiquitinated by USP51, leading to stabilization.

Disease relevance. Corneal dystrophy, posterior polymorphous, 3 (PPCD3) [MIM:609141] A subtype of posterior corneal dystrophy, a disease characterized by alterations of Descemet membrane presenting as vesicles, opacities or band-like lesions on slit-lamp examination and specular microscopy. Affected patient typically are asymptomatic. The disease is caused by variants affecting the gene represented in this entry. Corneal dystrophy, Fuchs endothelial, 6 (FECD6) [MIM:613270] A corneal disease caused by loss of endothelium of the central cornea. It is characterized by focal wart-like guttata that arise from Descemet membrane and develop in the central cornea, epithelial blisters, reduced vision and pain. Descemet membrane is thickened by abnormal collagenous deposition. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the delta-EF1/ZFH-1 C2H2-type zinc-finger family.

Isoforms (5)

UniProt ID	Names	Canonical?
P37275-1	1	yes
P37275-2	2
P37275-3	3
P37275-4	4
P37275-5	5

RefSeq proteins (40): NP_001121600, NP_001167564, NP_001167565, NP_001167566, NP_001167567, NP_001310570, NP_001310571, NP_001310572, NP_001310573, NP_001310574, NP_001310575, NP_001310576, NP_001310577, NP_001310578, NP_001310579, NP_001310580, NP_001310581, NP_001310582, NP_001310583, NP_001310584, NP_001310585, NP_001310586, NP_001310587, NP_001310588, NP_001310589, NP_001310590, NP_001310591, NP_001310592, NP_001310593, NP_001310594, NP_001310595, NP_001310600, NP_001310601, NP_001310602, NP_001310603, NP_001310604, NP_001310605, NP_001310606, NP_001310607, NP_110378 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR008598	Di19_Zn-bd	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR051574	ZnF_E-box_Homeobox	Family

Pfam: PF00096, PF05605

UniProt features (88 total): sequence conflict 17, cross-link 15, compositionally biased region 11, modified residue 11, sequence variant 11, zinc finger region 7, region of interest 7, splice variant 4, helix 3, chain 1, DNA-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2E19	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P37275-F1	48.64	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (26): 31, 33, 313, 322, 642, 679, 686, 693, 700, 702, 704, 186, 195, 307, 331, 335, 347, 347, 439, 493 …

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-9764725	Negative Regulation of CDH1 Gene Transcription
R-HSA-9926550	Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition

MSigDB gene sets: 563 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, CREL_01, TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP, RRAGTTGT_UNKNOWN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_CARTILAGE_DEVELOPMENT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_ACID_CHEMICAL, GOBP_REGULATION_OF_SMOOTH_MUSCLE_CELL_DIFFERENTIATION, GOBP_SMOOTH_MUSCLE_CELL_DIFFERENTIATION, GCANCTGNY_MYOD_Q6

GO Biological Process (28): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), pattern specification process (GO:0007389), central nervous system development (GO:0007417), regulation of mesenchymal cell proliferation (GO:0010464), negative regulation of keratinocyte proliferation (GO:0010839), regulation of transforming growth factor beta receptor signaling pathway (GO:0017015), cell differentiation (GO:0030154), regulation of T cell differentiation in thymus (GO:0033081), keratinocyte proliferation (GO:0043616), negative regulation of endothelial cell differentiation (GO:0045602), positive regulation of neuron differentiation (GO:0045666), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), embryonic camera-type eye morphogenesis (GO:0048596), embryonic skeletal system morphogenesis (GO:0048704), semicircular canal morphogenesis (GO:0048752), regulation of smooth muscle cell differentiation (GO:0051150), cartilage development (GO:0051216), cellular response to amino acid stimulus (GO:0071230), cochlea morphogenesis (GO:0090103), nervous system development (GO:0007399), cell population proliferation (GO:0008283), negative regulation of epithelial cell differentiation (GO:0030857), animal organ development (GO:0048513), embryonic morphogenesis (GO:0048598), epithelial cell proliferation (GO:0050673), negative regulation of epithelial cell proliferation (GO:0050680)

GO Molecular Function (10): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), E-box binding (GO:0070888), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Signaling by Interleukins	1
Regulation of CDH1 Gene Transcription	1
MITF-M-dependent gene expression	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
binding	2
negative regulation of DNA-templated transcription	1
multicellular organism development	1
multicellular organismal process	1
nervous system development	1
system development	1
mesenchymal cell proliferation	1
regulation of cell population proliferation	1
regulation of keratinocyte proliferation	1
keratinocyte proliferation	1
negative regulation of epithelial cell proliferation	1
transforming growth factor beta receptor signaling pathway	1
regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
regulation of cellular response to transforming growth factor beta stimulus	1
cellular developmental process	1
T cell differentiation in thymus	1
regulation of T cell differentiation	1
epithelial cell proliferation	1
negative regulation of epithelial cell differentiation	1
endothelial cell differentiation	1
regulation of endothelial cell differentiation	1
neuron differentiation	1
positive regulation of cell differentiation	1
regulation of neuron differentiation	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
embryonic camera-type eye development	1
embryonic eye morphogenesis	1
camera-type eye morphogenesis	1
embryonic organ morphogenesis	1
skeletal system morphogenesis	1
embryonic skeletal system development	1
tube morphogenesis	1
inner ear morphogenesis	1

Protein interactions and networks

STRING

3848 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZEB1	CTBP1	Q13363	992
ZEB1	HDAC1	Q13547	969
ZEB1	CDH1	P12830	961
ZEB1	SMARCA4	P51532	949
ZEB1	CTBP2	P56545	939
ZEB1	SMAD3	P84022	930
ZEB1	VIM	P08670	913
ZEB1	DNMT1	P26358	897
ZEB1	TWIST1	Q15672	890
ZEB1	CDH2	P19022	882
ZEB1	COL8A2	P25067	871
ZEB1	HDAC2	Q92769	869
ZEB1	SMAD2	Q15796	865
ZEB1	EP300	Q09472	864
ZEB1	CTNNB1	P35222	856

IntAct

46 interactions, top by confidence:

A	B	Type	Score
HDAC2	KDM1A	psi-mi:“MI:0914”(association)	0.890
ZEB1	CTBP1	psi-mi:“MI:0915”(physical association)	0.860
CTBP1	ZEB2	psi-mi:“MI:0914”(association)	0.800
CTBP1	KDM1A	psi-mi:“MI:0914”(association)	0.790
CTBP1	CBX4	psi-mi:“MI:0914”(association)	0.700
EN1	NFIB	psi-mi:“MI:2364”(proximity)	0.470
CDK6	ZEB1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
IFNL1	ZEB1	psi-mi:“MI:0914”(association)	0.350
SYNCRIP	ARHGAP32	psi-mi:“MI:0914”(association)	0.350
DCAF15	ARNT	psi-mi:“MI:0914”(association)	0.350
CTBP1	TAF15	psi-mi:“MI:0914”(association)	0.350
CTBP1	GSN	psi-mi:“MI:0914”(association)	0.350
CTBP2	ZEB2	psi-mi:“MI:0914”(association)	0.350
HDAC1		psi-mi:“MI:0914”(association)	0.350
HDAC2		psi-mi:“MI:0914”(association)	0.350
RBBP4	KPNA3	psi-mi:“MI:0914”(association)	0.350
	NFIB	psi-mi:“MI:0914”(association)	0.350
INSR	ATOX1	psi-mi:“MI:0914”(association)	0.350
TP53BP1	PSMD14	psi-mi:“MI:2364”(proximity)	0.270
STK38L	SH3PXD2B	psi-mi:“MI:2364”(proximity)	0.270
STK38L	CCDC187	psi-mi:“MI:2364”(proximity)	0.270
CTBP1	SEC16A	psi-mi:“MI:2364”(proximity)	0.270
SRF	ZNF292	psi-mi:“MI:2364”(proximity)	0.270
ELF2	SETD1A	psi-mi:“MI:2364”(proximity)	0.270
FEV	TAF4	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (277): ZEB1 (Affinity Capture-Western), ZEB1 (Affinity Capture-Western), ZEB1 (Affinity Capture-Western), EP300 (Affinity Capture-Western), ZEB1 (Biochemical Activity), CTBP2 (Affinity Capture-Western), CTBP1 (Affinity Capture-Western), SIRT1 (Affinity Capture-Western), USP7 (Affinity Capture-Western), CHEK1 (Affinity Capture-Western), ZEB1 (Affinity Capture-Western), ZEB1 (Reconstituted Complex), ATM (Affinity Capture-Western), ZEB1 (Biochemical Activity), ZEB1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IYX6, A0A1L8H0H2, A5X7A0, A7XYJ6, E1BE02, F6NSX9, F8VPJ6, O35914, O57415, P37275, P59598, P59759, Q03172, Q13029, Q2KHR2, Q3UH06, Q5EXX3, Q5R7F2, Q5ZIE8, Q5ZLR2, Q62947, Q63755, Q64318, Q6NRM0, Q6ZPY7, Q76L83, Q7LBC6, Q7YR76, Q80VX4, Q86V15, Q8BHZ4, Q8BLG0, Q8BRH4, Q8BX22, Q8BZ32, Q8C0C0, Q8IZQ8, Q8NEZ4, Q8R5I7, Q8VIM5

Diamond homologs: A0A1L8FFY5, A0A1W2PPF3, A0JNI8, A1L0Z1, A1L2U9, A2PZF9, B0XS89, B1WAZ8, B1WBU4, G5EBU4, G5EC36, G5EE86, G5EEA1, O60315, O62836, O73590, P08048, P09088, P10925, P17010, P17012, P20154, P20662, P20912, P28166, P29674, P31362, P31363, P34764, P34765, P36197, P36198, P36200, P37137, P37275, P42571, P48742, P49335, P50458, P52739

SIGNOR signaling

24 interactions.

A	Effect	B	Mechanism
SMARCA4	up-regulates	ZEB1	binding
DAB2IP	“down-regulates quantity by repression”	ZEB1	“transcriptional regulation”
SALL4	“up-regulates quantity by expression”	ZEB1	“transcriptional regulation”
ZEB1	“down-regulates quantity by repression”	CDH1	“transcriptional regulation”
ZEB1	“down-regulates quantity by repression”	EPCAM	“transcriptional regulation”
ZEB1	“down-regulates quantity by repression”	GRHL2	“transcriptional regulation”
GRHL2	“down-regulates quantity by repression”	ZEB1	“transcriptional regulation”
LBX1	“up-regulates quantity by expression”	ZEB1	“transcriptional regulation”
ZEB1	“down-regulates quantity by repression”	FBP1	“transcriptional regulation”
FBXO45	“down-regulates quantity by destabilization”	ZEB1	binding
“Skp1-Pam E3”	“down-regulates quantity by destabilization”	ZEB1	polyubiquitination
ATM	“up-regulates activity”	ZEB1	phosphorylation
SNAI1	“up-regulates quantity by expression”	ZEB1	“transcriptional regulation”
hsa-miR-200a-3p	“down-regulates quantity by destabilization”	ZEB1	“post transcriptional regulation”
hsa-mir-200b-3p	“down-regulates quantity by destabilization”	ZEB1	“post transcriptional regulation”
hsa-miR-200c-3p	“down-regulates quantity by destabilization”	ZEB1	“post transcriptional regulation”
hsa-miR-141-3p	“down-regulates quantity by destabilization”	ZEB1	“post transcriptional regulation”
miR-429	“down-regulates quantity by destabilization”	ZEB1	“post transcriptional regulation”
mir-205	“down-regulates quantity by destabilization”	ZEB1	“post transcriptional regulation”
ZEB1	“up-regulates quantity by expression”	VIM	“transcriptional regulation”
ZEB1	“down-regulates quantity by destabilization”	mir-205	“post transcriptional regulation”
ZEB1	“down-regulates quantity by destabilization”	hsa-miR-200a-3p	“post transcriptional regulation”
ZEB1	“down-regulates quantity by destabilization”	hsa-mir-200b-3p	“post transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 55 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Negative Regulation of CDH1 Gene Transcription	8	24.7×	3e-07
Regulation of PTEN gene transcription	5	22.9×	4e-04
Transcriptional regulation by RUNX1	5	18.8×	6e-04
Factors involved in megakaryocyte development and platelet production	5	8.5×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	5	26.9×	1e-04
transcription by RNA polymerase II	8	10.4×	1e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 6 cancer types — GBM, LUAD, LUSC, NPC, PCM, SCLC.

Clinical variants and AI predictions

ClinVar

209 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	21
Likely pathogenic	7
Uncertain significance	127
Likely benign	22
Benign	17

Top pathogenic / likely-pathogenic (28)

Variant ID	HGVS	Classification
12631	NM_001174096.2(ZEB1):c.2919_2920del (p.Gly974fs)	Pathogenic
12632	NM_001174096.2(ZEB1):c.1351C>T (p.Gln451Ter)	Pathogenic
2028102	NM_001174096.2(ZEB1):c.400C>T (p.Gln134Ter)	Pathogenic
2033644	NM_001174096.2(ZEB1):c.1890del (p.Phe630fs)	Pathogenic
2443788	NM_001174096.2(ZEB1):c.1923G>T (p.Gln641His)	Pathogenic
2443789	NM_001174096.2(ZEB1):c.2252C>A (p.Ser751Ter)	Pathogenic
2500583	NM_001174096.2(ZEB1):c.1485dup (p.Glu496fs)	Pathogenic
2571620	NM_001174096.2(ZEB1):c.1586_1595del (p.Asp529fs)	Pathogenic
2694368	NM_001174096.2(ZEB1):c.862dup (p.Ile288fs)	Pathogenic
2853981	NM_001174096.2(ZEB1):c.1972A>T (p.Lys658Ter)	Pathogenic
2856261	NM_001174096.2(ZEB1):c.482_483del (p.Asn161fs)	Pathogenic
3257351	NM_001174096.2(ZEB1):c.1812del (p.Asn604fs)	Pathogenic
3726715	NM_001174096.2(ZEB1):c.2236G>T (p.Glu746Ter)	Pathogenic
374184	NM_001174096.2(ZEB1):c.976C>T (p.Arg326Ter)	Pathogenic
4204860	NM_001174096.2(ZEB1):c.787_789delinsTAA (p.His263Ter)	Pathogenic
437319	NM_001174096.2(ZEB1):c.1579dup (p.Val527fs)	Pathogenic
4713282	NM_001174096.2(ZEB1):c.1063G>T (p.Glu355Ter)	Pathogenic
4719878	NM_001174096.2(ZEB1):c.1281_1285del (p.Arg427fs)	Pathogenic
4838558	NM_001174096.2(ZEB1):c.327dup (p.Asp110fs)	Pathogenic
503716	NM_001174096.2(ZEB1):c.1335_1338del (p.Ile445fs)	Pathogenic
817540	NM_001174096.2(ZEB1):c.1696G>T (p.Glu566Ter)	Pathogenic
1032236	NM_001174096.2(ZEB1):c.504del (p.Gln169fs)	Likely pathogenic
1300210	NM_001174096.2(ZEB1):c.623dup (p.Tyr208Ter)	Likely pathogenic
1300211	NM_001174096.2(ZEB1):c.688-1G>A	Likely pathogenic
2434683	NM_001174096.2(ZEB1):c.1859del (p.Asn620fs)	Likely pathogenic
2444117	NM_001174096.2(ZEB1):c.831del (p.Ser279fs)	Likely pathogenic
4292343	NM_001174096.2(ZEB1):c.1448del (p.Pro483fs)	Likely pathogenic
4532235	NM_001174096.2(ZEB1):c.361C>T (p.Gln121Ter)	Likely pathogenic

SpliceAI

2877 predictions. Top by Δscore:

Variant	Effect	Δscore
10:31387118:CCTTA:C	acceptor_loss	1.0000
10:31387119:CTTAG:C	acceptor_loss	1.0000
10:31387120:TTA:T	acceptor_loss	1.0000
10:31387121:TA:T	acceptor_loss	1.0000
10:31387122:A:AG	acceptor_gain	1.0000
10:31387122:A:AT	acceptor_loss	1.0000
10:31387123:G:A	acceptor_loss	1.0000
10:31387123:G:GG	acceptor_gain	1.0000
10:31387123:GGACA:G	acceptor_gain	1.0000
10:31388380:G:GT	donor_gain	1.0000
10:31461030:A:AG	acceptor_gain	1.0000
10:31461033:ACAG:A	acceptor_loss	1.0000
10:31461034:C:G	acceptor_gain	1.0000
10:31461034:CA:C	acceptor_loss	1.0000
10:31461035:A:AC	acceptor_loss	1.0000
10:31461035:A:AG	acceptor_gain	1.0000
10:31461036:G:GT	acceptor_gain	1.0000
10:31461036:GT:G	acceptor_gain	1.0000
10:31461036:GTT:G	acceptor_gain	1.0000
10:31461036:GTTA:G	acceptor_gain	1.0000
10:31461036:GTTAC:G	acceptor_gain	1.0000
10:31461233:TGACA:T	donor_gain	1.0000
10:31461234:GACA:G	donor_gain	1.0000
10:31461234:GACAG:G	donor_gain	1.0000
10:31461235:ACA:A	donor_gain	1.0000
10:31461236:CA:C	donor_gain	1.0000
10:31461237:AGT:A	donor_loss	1.0000
10:31461238:G:GG	donor_gain	1.0000
10:31461239:T:G	donor_loss	1.0000
10:31502346:A:AG	acceptor_gain	1.0000

AlphaMissense

1927 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:31510705:T:C	C172R	1.000
10:31510795:T:C	C202R	1.000
10:31510804:T:A	C205S	1.000
10:31510804:T:C	C205R	1.000
10:31510805:G:A	C205Y	1.000
10:31510805:G:C	C205S	1.000
10:31510806:C:G	C205W	1.000
10:31510816:T:C	F209L	1.000
10:31510817:T:C	F209S	1.000
10:31510818:T:A	F209L	1.000
10:31510818:T:G	F209L	1.000
10:31514642:T:A	C242S	1.000
10:31514642:T:C	C242R	1.000
10:31514643:G:C	C242S	1.000
10:31514644:C:G	C242W	1.000
10:31514651:T:C	C245R	1.000
10:31514663:T:C	F249L	1.000
10:31514664:T:C	F249S	1.000
10:31514665:C:A	F249L	1.000
10:31514665:C:G	F249L	1.000
10:31514682:T:C	L255P	1.000
10:31514690:C:A	H258N	1.000
10:31514690:C:G	H258D	1.000
10:31514691:A:C	H258P	1.000
10:31514691:A:G	H258R	1.000
10:31514692:C:A	H258Q	1.000
10:31514692:C:G	H258Q	1.000
10:31514702:C:G	H262D	1.000
10:31520143:T:A	C270S	1.000
10:31520143:T:C	C270R	1.000

dbSNP variants (sampled 300 via entrez): RS1000033107 (10:31372380 C>T), RS1000036847 (10:31401452 G>A), RS1000039961 (10:31528802 T>C), RS1000070150 (10:31355072 T>C,G), RS1000091758 (10:31528269 T>A,C), RS1000102649 (10:31431976 A>G), RS1000108766 (10:31412590 C>T), RS1000110151 (10:31448794 G>A), RS1000131118 (10:31418609 G>A), RS1000133930 (10:31339918 T>C,G), RS1000137698 (10:31518167 C>A), RS1000151485 (10:31484834 T>C), RS1000157704 (10:31427165 C>T), RS1000158331 (10:31382792 A>G), RS1000175840 (10:31453112 G>C)

Disease associations

OMIM: gene MIM:189909 | disease phenotypes: MIM:613270, MIM:609141, MIM:122000

GenCC curated gene-disease

Disease	Classification	Inheritance
posterior polymorphous corneal dystrophy 3	Definitive	Autosomal dominant
corneal dystrophy, Fuchs endothelial, 6	Strong	Autosomal dominant
corpus callosum, agenesis of	Moderate	Autosomal dominant
posterior polymorphous corneal dystrophy	Supportive	Autosomal dominant
Fuchs’ endothelial dystrophy	Supportive	Autosomal dominant

Mondo (8): corneal dystrophy, Fuchs endothelial, 6 (MONDO:0013206), posterior polymorphous corneal dystrophy 3 (MONDO:0012200), posterior polymorphous corneal dystrophy (MONDO:0020364), posterior polymorphous corneal dystrophy 1 (MONDO:0007378), corneal dystrophy (MONDO:0018102), glaucoma (MONDO:0005041), Fuchs’ endothelial dystrophy (MONDO:0005321), corpus callosum, agenesis of (MONDO:0009022)

Orphanet (3): Fuchs endothelial corneal dystrophy (Orphanet:98974), Posterior polymorphous corneal dystrophy (Orphanet:98973), Corneal dystrophy (Orphanet:34533)

HPO phenotypes

32 total (30 of 32 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000023	Inguinal hernia
HP:0000483	Astigmatism
HP:0000491	Keratitis
HP:0000501	Glaucoma
HP:0000533	Chorioretinal atrophy
HP:0000563	Keratoconus
HP:0000565	Esotropia
HP:0000572	Visual loss
HP:0000613	Photophobia
HP:0000622	Blurred vision
HP:0000632	Lacrimation abnormality
HP:0000646	Amblyopia
HP:0000662	Nyctalopia
HP:0000969	Edema
HP:0001131	Corneal dystrophy
HP:0003581	Adult onset
HP:0007663	Reduced visual acuity
HP:0007906	Ocular hypertension
HP:0007957	Corneal opacity
HP:0009918	Ectopia pupillae
HP:0011483	Anterior synechiae of the anterior chamber
HP:0011488	Abnormal corneal endothelium morphology
HP:0011490	Abnormal Descemet membrane morphology
HP:0011491	Reduced number of corneal endothelial cells
HP:0012038	Corneal guttata
HP:0012040	Corneal stromal edema
HP:0025358	Uveal ectropion
HP:0030857	Eye movement-induced pain
HP:0032122	Very low visual acuity

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000829_11	Waist-hip ratio	6.000000e-06
GCST004278_30	Pulse pressure	1.000000e-09
GCST005956_37	Waist-to-hip ratio adjusted for BMI	2.000000e-08
GCST005962_50	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	2.000000e-06
GCST009158_6	Uterine fibroids	2.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004343	waist-hip ratio
EFO:0005763	pulse pressure measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D061085	Agenesis of Corpus Callosum	C10.500.034; C16.131.666.034; C23.300.008
D003317	Corneal Dystrophies, Hereditary	C11.204.236; C11.270.162; C16.320.290.162
D005642	Fuchs’ Endothelial Dystrophy	C11.204.236.438; C11.270.162.438; C16.320.290.162.410
D005901	Glaucoma	C11.525.381
C567675	Corneal Dystrophy, Fuchs Endothelial, 6 (supp.)
C563788	Corneal Dystrophy, Posterior Polymorphous, 3 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

Clinical evidence (CIViC)

Drug × variant × indication: 5 predictive associations from 5 curated evidence items; also 1 prognostic, 1 oncogenic.

Variant	Therapy	Indication	Effect	Level	CIViC
ZEB1 Expression	Salinomycin	Mantle Cell Lymphoma	Sensitivity/Response	CIViC D	EID12500
ZEB1 Expression	Salinomycin + Doxorubicin	Mantle Cell Lymphoma	Sensitivity/Response	CIViC D	EID900
ZEB1 Expression	Vincristine	Mantle Cell Lymphoma	Resistance	CIViC D	EID12502
ZEB1 Expression	Oxaliplatin	Colon Cancer	Resistance	CIViC D	EID8086
ZEB1 Expression	Doxorubicin + Cytarabine + Gemcitabine	Mantle Cell Lymphoma	Resistance	CIViC D	EID899

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

117 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, decreases reaction, increases abundance, increases expression (+1 more)	11
Valproic Acid	affects cotreatment, decreases expression, affects expression	9
Resveratrol	decreases reaction, increases reaction, increases expression, increases methylation, decreases expression	5
Estradiol	affects cotreatment, increases expression	4
Cadmium Chloride	decreases expression, increases abundance, increases expression	4
trichostatin A	affects cotreatment, decreases expression	3
Arsenic	decreases reaction, increases abundance, increases expression, affects methylation	3
Benzo(a)pyrene	affects methylation, decreases expression, increases expression	3
Cadmium	decreases expression, increases abundance, increases expression, increases methylation, decreases reaction	3
Doxorubicin	affects cotreatment, decreases expression, affects response to substance	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
nickel sulfate	decreases expression, increases expression	2
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment, decreases expression	2
cordycepin	affects cotreatment, increases reaction, decreases expression, decreases localization	2
entinostat	decreases expression, affects cotreatment	2
Arsenic Trioxide	increases reaction, increases response to substance, decreases expression	2
Panobinostat	affects cotreatment, decreases expression	2
Acrolein	increases abundance, affects cotreatment, decreases expression, increases oxidation	2
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases oxidation	2
Formaldehyde	decreases expression	2
Ozone	affects cotreatment, decreases expression, increases oxidation, increases abundance	2
Silver	increases expression	2
Tretinoin	decreases expression, increases reaction	2
Cyclosporine	increases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	decreases expression	1
thymoquinone	decreases expression, increases reaction	1
bufotalin	decreases expression	1

Cellosaurus cell lines

9 cell lines: 8 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B8S0	Abcam HCT 116 ZEB1 KO	Cancer cell line	Male
CVCL_B9CL	Abcam MCF-7 ZEB1 KO	Cancer cell line	Female
CVCL_B9UJ	Abcam A-549 ZEB1 KO	Cancer cell line	Male
CVCL_E1DP	Ubigene THP-1 ZEB1 KO	Cancer cell line	Male
CVCL_HD03	HEK293 eGFP-ZEB1	Transformed cell line	Female
CVCL_TZ11	HAP1 ZEB1 (-) 1	Cancer cell line	Male
CVCL_XV26	HAP1 ZEB1 (-) 2	Cancer cell line	Male
CVCL_XV27	HAP1 ZEB1 (-) 3	Cancer cell line	Male
CVCL_XV28	HAP1 ZEB1 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

355 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00781027	PHASE4	COMPLETED	Fuchs’ Torsional Phaco Study
NCT03249337	PHASE4	RECRUITING	Glanatec(R) for Descemet Stripping in Fuch’s Endothelial Dystrophy
NCT05716945	PHASE4	RECRUITING	The OPTIMISE Study
NCT00061503	PHASE4	COMPLETED	Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
NCT00143208	PHASE4	COMPLETED	Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
NCT00224289	PHASE4	COMPLETED	Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00273221	PHASE4	UNKNOWN	Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial
NCT00329095	PHASE4	COMPLETED	An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00346489	PHASE4	COMPLETED	Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C
NCT00347035	PHASE4	TERMINATED	INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE
NCT00347802	PHASE4	COMPLETED	Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%
NCT00347841	PHASE4	COMPLETED	Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
NCT00348023	PHASE4	COMPLETED	Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension
NCT00348062	PHASE4	COMPLETED	A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
NCT00348400	PHASE4	COMPLETED	Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
NCT00351429	PHASE4	COMPLETED	Study of PGA Suture in Ophthalmology
NCT00376974	PHASE4	UNKNOWN	The Effect of Education on Patient Compliance
NCT00379834	PHASE4	COMPLETED	12-Month Stability of Diurnal IOP Control on Cosopt
NCT00382226	PHASE4	COMPLETED	IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
NCT00404729	PHASE4	COMPLETED	Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
NCT00440011	PHASE4	COMPLETED	Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
NCT00440141	PHASE4	COMPLETED	Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
NCT00442312	PHASE4	UNKNOWN	Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy
NCT00444184	PHASE4	COMPLETED	24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
NCT00444665	PHASE4	COMPLETED	Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
NCT00449098	PHASE4	UNKNOWN	Ologen (OculusGen)-Glaucoma MMC Control Trial in India
NCT00466479	PHASE4	COMPLETED	Brimonidine vs ALTP in Progressing Human Glaucoma
NCT00468429	PHASE4	UNKNOWN	Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery
NCT00468988	PHASE4	COMPLETED	Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
NCT00471380	PHASE4	COMPLETED	A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
NCT00485238	PHASE4	UNKNOWN	ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function
NCT00486486	PHASE4	COMPLETED	24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
NCT00519753	PHASE4	COMPLETED	Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
NCT00541242	PHASE4	COMPLETED	Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00557232	PHASE4	COMPLETED	Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
NCT00597181	PHASE4	TERMINATED	A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy
NCT00607685	PHASE4	COMPLETED	5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy
NCT00626067	PHASE4	COMPLETED	Study of Patient Use and Perception of the Travatan Dosing Aid
NCT00666237	PHASE4	COMPLETED	Primary Tube Versus Trabeculectomy Study